尼达尼布治疗特发性肺纤维化患者细胞外基质周转生物标志物(INMARK研究):一项随机安慰剂对照研究
INMARK试验纳入347例特发性肺纤维化且FVC≥80%预计值的患者,随机接受尼达尼布150mg每日两次或安慰剂治疗12周。主要终点CRPM变化率两组无显著差异,但尼达尼布组FVC下降速率显著低于安慰剂组。在安慰剂后开放标签尼达尼布的患者中,CRPM升高与52周疾病进展相关。
要点
- 尼达尼布未改变CRPM变化率,提示CRPM不是尼达尼布疗效标志物。
- 安慰剂期CRPM升高与后续52周疾病进展相关。
核心结论
- 在特发性肺纤维化且肺功能保留的患者中,尼达尼布治疗12周未影响CRPM变化率,但减缓了FVC下降速率。
- CRPM变化不是尼达尼布治疗反应的标志物。
研究设计与样本
- 随机、双盲、安慰剂对照试验,纳入347例诊断特发性肺纤维化3年内且FVC≥80%预计值的患者,按1:2随机分配至尼达尼布150mg每日两次(n=116)或安慰剂(n=231)治疗12周,随后开放标签尼达尼布40周。
- 主要终点为意向治疗人群中基线至第12周CRPM变化率。
主要发现
- 接受安慰剂12周后开放标签尼达尼布的患者中,12周内CRPM浓度升高与52周疾病进展(FVC绝对下降≥10%预计值或死亡)相关。
- 双盲期严重不良事件:尼达尼布组8例(7%),安慰剂组18例(8%);3级腹泻:尼达尼布组2例(2%),安慰剂组2例(1%)。
临床怎么用
- 尼达尼布可减缓特发性肺纤维化患者FVC下降,支持其用于肺功能保留的患者。
- CRPM不宜作为尼达尼布治疗反应的生物标志物。
局限性
- 研究仅治疗12周,长期影响未知。
- 开放标签阶段结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A hallmark of idiopathic pulmonary fibrosis is the excess accumulation of extracellular matrix in the lungs. Degradation of extracellular matrix generates free-circulating protein fragments called neoepitopes. The aim of the INMARK trial was to investigate changes in neoepitopes as predictors of disease progression in patients with idiopathic pulmonary fibrosis and the effect of nintedanib on these biomarkers. METHODS: In this randomised, double-blind, placebo-controlled trial, patients with a diagnosis of idiopathic pulmonary fibrosis within the past 3 years and forced vital capacity (FVC) of 80% predicted or higher were eligible to participate. Patients were recruited from hospitals, private practices, clinical research units, and academic medical centres. Patients were randomly assigned (1:2) with the use of a pseudo-random number generator to receive oral nintedanib 150 mg twice a day or placebo for 12 weeks in a double-blind fashion, followed by open-label nintedanib for 40 weeks. The primary endpoint was the rate of change in C-reactive protein (CRP) degraded by matrix metalloproteinases 1 and 8 (CRPM) from baseline to week 12 in the intention-to-treat population. The trial has been completed and is registered with ClinicalTrials.gov, number NCT02788474, and with the European Clinical Trials Database, number 2015-003148-38. FINDINGS: Between June 27, 2016, and May 15, 2017, 347 patients were randomly assigned to the nintedanib group (n=116) or to the placebo group (n=231). One patient from the placebo group was not treated owing to a randomisation error. At baseline, mean FVC was 97·5% (SD 13·5) predicted. In the double-blind period, 116 patients received nintedanib and 230 patients received placebo. The rate of change in CRPM from baseline to week 12 was -2·57 × 10-3 ng/mL/month in the nintedanib group and -1·90 × 10-3 ng/mL/month in the placebo group (between-group difference -0·66 × 10-3 ng/mL/month [95% CI -6·21 × 10-3 to 4·88 × 10-3]; p=0·8146). The adjusted rate of change in FVC over 12 weeks was 5·9 mL in the nintedanib group and -70·2 mL in the placebo group (difference 76·1 mL/12 weeks [31·7 to 120·4]). In patients who received placebo for 12 weeks followed by open-label nintedanib, rising concentrations of CRPM over 12 weeks were associated with disease progression (absolute decline in FVC ≥10% predicted or death) over 52 weeks. In the double-blind period, serious adverse events were reported in eight (7%) patients given nintedanib and 18 (8%) patients given placebo. Grade 3 diarrhoea was reported in two (2%) patients in the nintedanib group and two (1%) patients in the placebo group. No patients had grade 4 diarrhoea. INTERPRETATION: In patients with idiopathic pulmonary fibrosis and preserved lung function, treatment with nintedanib versus placebo for 12 weeks did not affect the rate of change in CRPM but was associated with a reduced rate of decline in FVC. These results suggest that change in CRPM is not a marker of response to nintedanib in patients with idiopathic pulmonary fibrosis. FUNDING: Boehringer Ingelheim.
引用
- Maher TM, Stowasser S, Nishioka Y, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019. PMID: 31326319. doi:10.1016/S2213-2600(19)30255-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。